Alterity Therapeutics commences US investor meetings following positive clinical data
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today commencing an investor roadshow in the US. The meetings follow the Company’s presentation of clinical data from its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting last week.
The data indicate that PBT434 was well tolerated with adverse event rates comparable to placebo and dose dependent systemic exposure following oral administration. Importantly, the results indicate that PBT434 not only crosses the blood brain barrier in humans, confirming previous observations in animal studies, but that clinically tested doses achieve concentrations in brain that exceed those associated with efficacy in animal models of disease. No serious adverse events were reported and no subject discontinued dosing with PBT434 due to adverse events.
Alterity’s CEO Mr. Geoffrey Kempler and Dr David Stamler, Chief Medical Officer & Senior VP Clinical Development will meet with sophisticated investors throughout the week to discuss:
- Significant progress over the last 12 months including the release of data from the Phase 1 clinical trial for PBT434, Orphan drug designation for PBT434 for the treatment of Multiple System Atrophy (MSA); and
- High unmet need for new treatment options for a range of neurological diseases and the potential of PBT434; and
- Strong commercial case for PBT434 in MSA; and
- Strategic investment led by Life Biosciences;
Mr. Geoffrey Kempler said: “We are very pleased with the strong response from investors in the US to our commitment and our progress to treat highly debilitating neurological diseases.”
The Company changed its name on 8 April 2019 from Prana Biotechnology Limited to Alterity Therapeutics Limited, (ASX: ATH, NASDAQ:ATHE).
Investor enquiries IR@alteritytherapeutics.com